Skip to main content
    Q

    Quoin Pharmaceuticals Ltd DRC (QNRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.03
    -0.07 (-1.71%)

    Market Cap: $19.94M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(17/28)
    Avg Surprise
    -1634.67%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.76
    Range$-2.05 - $-1.47
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.69-4.5%
    60d ago$-1.69-4.5%
    30d ago$-1.760.0%
    7d ago$-1.760.0%
    Current$-1.76
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.38
    Range$-2.10 - $-0.66
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.38---
    Sep 26EST
    		-$-1.76---
    Jun 26
    Reported Aug 14
    		$-1.90$-1.83-3.83%Miss+69.7%
    Mar 26
    Reported May 7
    		$-1.77$-2.26+21.68%Beat+72.8%
    Dec 25
    Reported Mar 26
    		$-1.74N/A+56.72%Beat-525.7%
    Sep 25
    Reported Nov 6
    		$-6.70$-1.92-248.96%Miss+59.4%
    Jun 25
    Reported Aug 7
    		$-6.28$-6.83+8.05%Beat+54.1%
    Mar 25
    Reported May 13
    		$-6.50$-4.20-54.76%Miss+83.2%
    Dec 24
    Reported Mar 13
    		$-0.28$-0.43+35.33%Beat+86.6%
    Sep 24
    Reported Nov 7
    		$-16.51$-0.40-4027.50%Miss+75.8%
    Jun 24
    Reported Aug 8
    		$-13.67$-20.30+32.66%Beat+81.4%
    Mar 24
    Reported May 9
    		$-38.62$-14.35-169.13%Miss+73.2%
    Dec 23
    Reported Mar 13
    		$-2.08$-2.31+9.96%Beat-407.3%
    Sep 23
    Reported Nov 8
    		$-68.25$-95.32+28.40%Beat+82.7%
    Jun 23
    Reported Aug 2
    		$-73.48$-96.60+23.93%Beat+94.6%
    Mar 23
    Reported May 8
    		$-144.10$-96.60-49.17%Miss-100.6%
    Dec 22
    Reported Mar 8
    		$-0.41$-0.62+33.87%Beat+99.9%
    Sep 22
    Reported Nov 10
    		$-395.26$-495.60+20.25%Beat+94.7%
    Jun 22
    Reported Aug 18
    		$-1360.80$-1158.15-17.50%Miss-755900.0%
    Mar 22
    Reported Apr 13
    		$22207.53$-4392.51+605.58%Beat+1272081.8%
    Dec 21
    Reported Mar 21
    		$-309.00$-0.73-41940.82%Miss-772400.0%
    Sep 21
    Reported Dec 17
    		$-7402.51$-1365.00-442.31%Miss-74025000.0%
    Jun 21
    Reported Aug 24
    		$-0.18N/AN/ABeat-350.0%
    Mar 21
    Reported Jun 16
    		$-1.75$0.00N/AMiss-17359.0%
    Dec 20
    Reported Mar 29
    		$-0.04$0.00N/AMiss+95.5%
    Sep 20
    Reported Nov 20
    		$-0.01$0.00N/AMiss+99.7%
    Jun 20
    Reported Aug 12
    		$-0.04$0.00N/AMiss+98.4%
    Mar 20
    Reported Apr 3
    		$-0.01$0.00N/AMiss+97.5%
    Dec 19
    Reported Mar 31
    		$-0.89$0.00N/AMiss+72.0%
    Sep 19
    Reported Nov 19
    		$-3.14$0.00N/AMiss+95.7%
    Jun 19
    Reported Aug 13
    		$-2.47$0.00N/AMiss+96.0%
    Mar 19
    Reported May 21
    		$-0.41$0.00N/AMiss+99.0%
    Dec 18
    Reported Mar 18
    		$-3.17$0.00N/AMiss+92.1%
    Sep 18
    Reported Nov 13
    		$-72.50$-70.00-3.57%Miss+26.0%
    Jun 18
    Reported Aug 9
    		$-62.50$-72.50+13.79%Beat-1853.1%
    Mar 18
    Reported May 17
    		$-40.00$-75.00+46.67%Beat-170.3%
    Dec 17
    Reported Mar 19
    		$-40.00$-77.50+48.39%Beat-128.6%
    Sep 17
    Reported Nov 22
    		$-98.00$-75.00-30.67%Miss-
    Jun 17
    Reported Aug 21
    		$-3.20N/A+94.18%Beat-
    Mar 17
    Reported May 29
    		$-14.80N/A+73.09%Beat-
    Dec 16
    Reported Mar 23
    		$-17.50N/A+65.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.33EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-576.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.76xQuick Ratio1.76x
    Trading Statistics
    Beta1.75Avg Volume49.51K
    52-Week High$23.5052-Week Low$3.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.41
    SMA 20$5.20
    SMA 50$5.67
    SMA 200$6.54
    EMA 10$4.48
    EMA 20$4.96
    EMA 50$5.34
    EMA 200$6.39

    MACD

    Line: -0.53Signal: -0.41Hist: -0.12

    ADX

    ADX: 27.9+DI: 16.5-DI: 26.6

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down100.0
    PSAR$4.89

    Bollinger Bands

    Upper Band$7.38
    Lower Band$3.03
    %B Position8347%(Upper)
    Band Width0.23

    RSI (14-Day)

    Oversold
    27.9

    Momentum Oscillators

    Stoch %K3.9
    Stoch %D3.8
    Williams %R-95.2
    ROC (10d)-14.6%
    Momentum-0.69
    CCI (20d)-87.1
    MFI (14d)22.2

    Volatility Measures

    ATR (14d)$0.53(13.1%)
    StdDev (20d)1.09
    Hist Vol77.1%(High)

    Volume Flow

    VWAP$4.03
    OBV84.8M
    AD Line-43.0M
    CMF (20d)-0.309

    Volume Metrics

    Avg Vol (20d)50.5K
    Vol Ratio0.5x(Low)
    VWMA (20d)$4.95

    Pivot Points

    R3$4.67
    R2$4.48
    R1$4.29
    Pivot Point$4.10
    S1$3.91
    S2$3.72
    S3$3.53

    Advanced Oscillators

    TSI-33.19
    Ultimate Osc32.4
    KST-266.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$100,370$0$0$0$154,774$0
    Cost of Revenue$25,429$24,932$25,156N/A$25,520$24,870$25,199$25,074$24,908$25,277$25,952$25,915
    Gross Profit$-25,429$-24,932$-25,156N/A$-25,520$-24,870$50,185$-25,074$-24,908$-25,277$-25,952$-25,915
    Operating Expenses$5.54M$5.13M$4.52M$4.02M$3.79M$3.96M$2.41M$2.53M$2.14M$2.46M$2.22M$2.13M
    R&D$3.66M$3.43M$3.10M$2.28M$2.05M$2.37M$1.07M$1.17M$587,503$885,298$832,391$758,759
    SG&A$1.85M$1.70M$1.42M$1.74M$1.74M$1.58M$1.33M$1.36M$1.55M$1.57M$1.39M$1.37M
    Operating Income$-5,567,562$-5,131,210$-4,520,435$-4,019,925$-3,793,179$-3,957,177$-2,405,061$-2,528,002$-2,137,118$-2,458,284$-2,217,667$-2,125,223
    Interest Income$100,947$146,775$171,698$62,266$103,245$144,872$109,328$146,388$165,262$137,513$158,546$196,425
    Interest Expense$0$0$0$0$0$0$0$0$0$0$218,919$0
    Income Before Tax$-5,463,270$-4,997,735$-4,348,373$-3,948,165$-3,695,938$-3,812,179$-2,311,274$-2,349,885$-1,974,033$-2,327,280$-2,049,878$-1,926,679
    Income Tax Expense$0$0$0$0$0$0$-1,966,838$-8,953,466,991$1.97M$2$2.07M$-23,891
    Net Income$-5,463,270$-4,997,735$-4,348,373$-3,948,165$-3,695,938$-3,812,179$-2,311,274$-2,349,885$-1,974,033$-2,327,280$-2,049,878$-1,926,679
    EBITDA$-5,542,133$-5,092,910$-4,323,373$-3,923,165$-3,670,938$-3,787,179$-2,286,274$-2,324,885$-1,949,033$-2,302,280$-2,024,204$-1,900,669
    EBIT$-5,567,562$-5,117,910$-4,348,373$-3,948,165$-3,695,938$-3,812,179$-2,311,274$-2,349,885$-1,974,033$-2,327,280$-2,049,878$-1,926,679
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QNRX

    News

    Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

    Quoin Pharmaceuticals announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its lead product candidate, QRX003...

    GlobeNewswire•10/14/26•Bullish

    Europe gives a rare skin disease drug special status. Approval could bring 10 years' exclusivity.

    Quoin Pharmaceuticals' QRX003 has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for Peeling Skin Syndrome...

    Stock Titan•10/14/26•Bullish

    Quoin Pharmaceuticals' QRX003 Secures EMA Orphan Drug Designation for Peeling Skin Syndrome Treatment

    Quoin Pharmaceuticals Ltd. announced that its lead drug candidate, QRX003, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the treatment of Peeling Skin Syndrome. This designation...

    Kalkine Media•10/14/26•Bullish

    BTIG Initiates Quoin Pharmaceuticals(QNRX.US) With Buy Rating, Announces Target Price $14

    BTIG analyst Jeet Mukherjee has initiated coverage on Quoin Pharmaceuticals (QNRX.US) with a "buy" rating and set a target price of $14. Mukherjee has a 46.6% success rate and an average return of 11.5% over the past...

    Moomoo•10/12/26•Bullish

    BTIG initiates Quoin Pharmaceuticals stock with buy rating By Investing.com

    BTIG has initiated coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a "buy" rating and a price target of $14.00, suggesting significant upside despite a 78% stock decline over the past year. The company...

    Investing.com India•10/12/26•Bullish

    QNRX Valuation and Fair Value

    P/E
    -0.3x
    P/B
    2.1x
    See GNG's fair value

    QNRX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -576.0%

    QNRX Competitors

    CompanyTicker
    Scilex Holding CompanySCLX
    Vyne Therapeutics IncVYNE
    Cocrystal Pharma IncCOCP
    Entero Therapeutics, Inc.ENTO
    PAVmed IncPAVM
    SeaStar Medical Holding CorporationICU
    Universe Pharmaceuticals IncUPC
    Modular Medical IncMODD

    Sector: Healthcare

    QNRX Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    QNRX Bull Case vs Bear Case

    Bull case

    • 100.0% of QNRX's analyst ratings are Buy or Strong Buy.

    QNRX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -526.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.76
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About QNRX

    Does QNRX pay dividends?

    Quoin Pharmaceuticals Ltd DRC (QNRX) does not currently pay a regular dividend.

    What is QNRX's market cap?

    Quoin Pharmaceuticals Ltd DRC (QNRX) has a market capitalization of $19.94M with a current stock price of $4.03.

    Related stocks

    Sector: Healthcare

    All stocks starting with Q

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In